SOURCE: Generex Biotechnology Corporation

January 31, 2007 10:00 ET

Generex Biotechnology to Make Presentations at The Ramanbhai Foundation 3rd International Symposium

TORONTO -- (MARKET WIRE) -- January 31, 2007 -- Generex Biotechnology Corporation (NASDAQ: GNBT) announced today that it will be making four poster presentations at The Ramanbhai Foundation 3rd International Symposium ( entitled "Advances in Diabetes Therapy - Basic Science and Clinical Aspects" at the Zydus Research Centre ( in Ahmedabad, India, February 1 - 4, 2007.

The Company will be making the following poster presentations:

--  "Near Normalization of Metabolic Control in Type-1 DM Using
    Conventional Insulin Therapy and a 13-Point Method Designed to Enhance
    Compliance," by Doctors Marco Guevara-Aguirre, Jaime Guevara-Aguirre, and
    Jeannette Saavedra, all of the Institute of Endocrinology IEMYR, Quito,
    Ecuador, and Dr. Gerald Bernstein, the Company's Vice-President for Medical
--  "Pre-Prandial S.C. Regular Insulin Versus Prandial Generex Oral-
    lyn™ in Type-1 DM Subjects Maintained in Basal S.C. Twice Daily Isophane
    Insulin (NPH)," by Doctors Marco Guevara-Aguirre, Jaime Guevara-Aguirre,
    and Jeannette Saavedra.
--  "Generex Oral-lyn™ at Lunchtime in Juvenile Type-1 DM Subjects
    Maintained on Basal Glargine Insulin and Pre-Breakfast and Pre-Dinner
    Regular Insulin," by Doctors Marco Guevara-Aguirre, Jaime Guevara-Aguirre,
    Jeannette Saavedra, and Gerald Bernstein.
--  "Metformin Gum:  An Alternative Method for Delivery of Biguanides," by
    Doctors Marco Guevara-Aguirre, Jaime Guevara-Aguirre, and Jeannette
This symposium and the demonstration of the latest achievements in the efficacy of Generex Oral-lyn, the Company's proprietary oral insulin spray product, coincide with the Company's effort to access the Indian market as the Company is in the process of registering Generex in Mumbai to pursue the governmental approval for the importation, marketing, distribution, and sale of Generex Oral-lyn in India.

There are more than 35,500,000 adults with diabetes in India, a prevalence of 5.9% which is expected to rise to 8.1% by 2025 (73,475,900) (International Diabetes Federation, 2003), and with the economic burden of diabetes and its complications growing rapidly, the solution lies in alternative approaches to treatment and prevention. The Company believes that Generex Oral-lyn and its Metformin gum product are poised to provide a significant part of that solution.

About Generex

Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. The Company's flagship product, oral insulin (Generex Oral-lyn™), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. For more information, visit the Generex website at

Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Contact Information

  • For more information, please contact:

    For Generex:

    Shayne Gilliatt
    of Generex
    or 416-364-2551

    Andrew Hellman
    of CEOcast, Inc.

    Michael Smith
    of Rubenstein Public Relations
    Email Contact